Delphine Loirat

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 609 citations

Medicine, Oncology, Pharmacotherapy +16

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet · 2023 · 427 citations · Full text

Medicine, Oncology, Pharmacology +17

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara M. Tolaney, Kevin Punie et al. · Annals of Oncology · 2021 · 299 citations · Full text

Medicine, Oncology, Pharmacology +16

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · Journal of Clinical Oncology · 2022 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17